GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Construction will begin this year with the new capacity anticipated by 2025
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty unlawfully infringes patents Moderna filed between 2010 and 2016
Collaboration supports multiple discovery efforts, including vaccines
Site Enhances New Modality CRDMO Platform Capacity for Customers
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Subscribe To Our Newsletter & Stay Updated
